CJC-1295: uses, research, and legal status

What is CJC-1295?

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). It is studied for its ability to raise growth hormone and IGF-1 levels and is commonly discussed in combination with ipamorelin.

It is not an FDA-approved drug and falls within the peptides affected by the 2026 compounding review.

How it is thought to work

CJC-1295 acts on the GHRH pathway to encourage the pituitary to release growth hormone. Some versions are designed to extend its activity in the body, which a provider would account for in any protocol.

What the research shows

Small studies have examined effects on GH and IGF-1 levels. Larger, long-term human outcome data is limited, so a provider can set realistic expectations.

Studied uses

• Growth-hormone and IGF-1 support
• Recovery and body-composition protocols
• Commonly combined with ipamorelin

Legal status in 2026

CJC-1295 is not FDA-approved and is among the peptides under federal review in 2026. No rule has changed yet, and it would remain prescription-only even if reclassified.

How to access CJC-1295 legitimately

A licensed provider evaluates suitability, often with baseline bloodwork, and where permitted prescribes through a licensed compounding pharmacy.

PeptideForward can match you with vetted telehealth providers who handle these therapies through legitimate channels. The eligibility check takes about five minutes and there is no cost to see if you are a candidate.

Frequently asked questions

Why is it paired with ipamorelin? The two act through complementary pathways to support growth-hormone release. A provider decides whether any combination is appropriate.

Is it legal now? It is not an approved drug. Where permitted, it requires a prescription. Its compounding status is part of the 2026 review.

Does PeptideForward sell it? No. We connect you with licensed providers only.